Turing spot patterns underlying the branching patterns. by Hui Xu (9203)

Percentage of the predicted <i>CYP2C19</i> (A), <i>CYP3A5</i> (B), <i>DPYD</i> (C), <i>CYP2C9</i> (D), <i>TPMT</i> (E), <i>NUDT15</i> (F) metabolizer groups. by Ewa Goljan (3463487)

Subjects:

Relationship between the interface velocities and the decreases of temperature at the interface for four solutions (1mg/mL). by Naoto Nishi (2735446)

Image_2_Long-Term Elevated Inflammatory Protein Levels in Asymptomatic SARS-CoV-2 Infected Individuals.tif by Liina Tserel (420665)

“…We here studied the antibody and T cell responses, and a wide range of inflammation markers, in 56 SARS-CoV-2 antibody-positive individuals, identified by a population screen after the first wave of SARS-CoV-2 infection. …”

Image_3_Long-Term Elevated Inflammatory Protein Levels in Asymptomatic SARS-CoV-2 Infected Individuals.tif by Liina Tserel (420665)

“…We here studied the antibody and T cell responses, and a wide range of inflammation markers, in 56 SARS-CoV-2 antibody-positive individuals, identified by a population screen after the first wave of SARS-CoV-2 infection. …”

Image_1_Long-Term Elevated Inflammatory Protein Levels in Asymptomatic SARS-CoV-2 Infected Individuals.tif by Liina Tserel (420665)

“…We here studied the antibody and T cell responses, and a wide range of inflammation markers, in 56 SARS-CoV-2 antibody-positive individuals, identified by a population screen after the first wave of SARS-CoV-2 infection. …”

Adverse events and treatment interruptions. by Nicola Squillace (691608)

“…At T1, ART-experienced PLWH showed a significant reduction of total cholesterol (TC) and triglycerides, and a slight increase in blood glucose (BG) and ALT. …”

Flow chart of the treatment interruptions. by Nicola Squillace (691608)

“…At T1, ART-experienced PLWH showed a significant reduction of total cholesterol (TC) and triglycerides, and a slight increase in blood glucose (BG) and ALT. …”

Addition of amiloride, inhibition of actin polymerization, or PKC inhibition decreased CXCL1 internalization in DIH cells. by Yani Zhao (336703)

“…<p>DIH cells were pre-treated with various inhibitors prior to incubation with ¹²⁵I-CXCL1/GRO-α for the specified time points, as described in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0029624#s4" target="_blank">Materials and Methods</a>. …”

Virulence dependent inhibition of glycolysis in <i>S</i>. Typhimurium infected macrophages. by Saray Gutiérrez (11473528)

Morphine decreases neuronal excitability in enteric AHP +ve neurons without changing the resting membrane potential. by Tricia H. Smith (306217)

“…Statistical analysis (D) indicates that morphine (3 µM) causes a significant increase in threshold and a decrease in action potential height (taken at 30% height at 0.09 nA current injection) while leaving the resting membrane potential unaffected (* = p<0.05 via t-test). n = 6 for all analyses. …”

<i>GLIS3</i> KD decreases SRp55 expression in INS-1E cells. by Tatiane C. Nogueira (185100)

UV-B impairs PIF4 binding to shade marker genes’ promoters in a UVR8-dependent manner. by Eleni Tavridou (8822789)

Genes whose expression was decreased by 100 nM ouabain by more than 1.3-fold. by Larisa V. Smolyaninova (3600053)

Immune challenge increases the intensity of some Ni-Sp185/333 proteins and decreases the intensity of others. by Lauren S. Sherman (800584)

“…(B) After challenge with <i>V</i>. <i>diazotrophicus</i>, larger MW proteins decrease in intensity (compare white arrows in A and B), whereas the monomers increase in intensity (compare black arrows in A and B).…”

PA J10 mutant does not affect the formation of VLPs but decreases viral RNA packaging efficiency. by Yuhong Liang (335908)

Diagram showing some of the factors that mediate cytokin storm following infection with COVID-19. by Joseph Rabin (7399436)

Subjects:

Antibodies used for flow cytometry experiments. by Joseph Rabin (7399436)

Subjects:

Changes of plasma proinflammatory cytokines/chemokines during and after RA infusion. by Joseph Rabin (7399436)

Subjects:

Demographics of the COVID-19 patients who received regadenoson treatment. by Joseph Rabin (7399436)

Subjects: